Abstract |
Robust epidemiologic and genetic studies have solidified the role of lipoprotein (a) [Lp(a)] as an independent and causal risk factor for cardiovascular disease. The increased cardiovascular risk of Lp(a) is mediated through both proatherogenic and prothrombotic/ antifibrinolytic mechanisms. Several societies recommend Lp(a) screening for patients with high cardiovascular risk, although no consensus exists on the management of patients with elevated Lp(a). However, numerous pharmacologic approaches are being evaluated that have the potential to reduce Lp(a) and will be the focus of this review. The majority of these interventions have been developed for other lipid-lowering indications, but also lower Lp(a). There are also novel therapies in development that specifically target Lp(a). The efficacy of these therapies varies, and their role in the evolving lipoprotein therapeutic landscape has yet to be determined. Nevertheless, targeted Lp(a) reduction is certainly intriguing and will likely continue to be an active area of investigation in the future.
|
Authors | Lillian C Man, Erik Kelly, Danielle Duffy |
Journal | Current atherosclerosis reports
(Curr Atheroscler Rep)
Vol. 17
Issue 5
Pg. 502
(May 2015)
ISSN: 1534-6242 [Electronic] United States |
PMID | 25736345
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Cardiovascular Diseases
(blood, genetics)
- Disease Management
- Humans
- Lipoprotein(a)
(genetics, metabolism)
|